Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

The Cost of Managing Pleural Effusion Associated with Dasatinib in CML Patients Post Imatinib Failure.

Jennifer Stephens, Kim Carpiuc, Marc Botteman, WeiWei Feng, PhD, Richard C. Woodman, MD

Blood (2007) 110 (11): 4586.

https://doi.org/10.1182/blood.V110.11.4586.4586

Published: 2007

Journal Articles

Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.

Kim Carpiuc, Khalid El Ouagari, PhD, Jennifer Stephens, Marc Botteman, WeiWei Feng, PhD, Richard C. Woodman, MD

Blood (2007) 110 (11): 4587.

https://doi.org/10.1182/blood.V110.11.4587.4587

Published: 2007

Journal Articles

Comparison of 12-Month Treatment Costs for Patients with Advanced Phase Chronic Myeloid Leukemia (CML) in China: Imatinib (IM) vs. Chemotherapy (Chemo) Plus Interferon-(IFN) in Accelerated Phase (AP) CML and IM vs. Chemo in Blast Crisis (BC) CML.

Zi Chen, M.D., Ph.D., Chun Wang, M.D., Weiwei Feng, PhD

Blood (2007) 110 (11): 5169.

https://doi.org/10.1182/blood.V110.11.5169.5169

Published: 2007

Journal Articles

Imatinib Is Cost-Effective Comparing to Interferon-(IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective.

Chun Wang, M.D., Zi Chen, M.D., Ph.D., Weiwei Feng, PhD

Blood (2007) 110 (11): 5170.

https://doi.org/10.1182/blood.V110.11.5170.5170

Published: 2007

Journal Articles

Imatinib Versus Interferon-alpha (IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective: 12 Months Cost and Cost Per Responder Analyses.

Chun Wang, M.D., Zi Chen, M.D., Ph.D., Weiwei Feng, PhD

Blood (2007) 110 (11): 5171.

https://doi.org/10.1182/blood.V110.11.5171.5171

Published: 2007

Journal Articles

The Treatment Cost To Achieve a Complete Cytogenetic Response in Imatinib Resistant Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients: Nilotinib vs. Dasatinib.

Fabio D. Mataveli, MD, Weiwei Feng, PhD, Alessandra Calabró, MBA, Wellington Mendes, MD, Vania Hungria, MD, PhD

Blood (2007) 110 (11): 3327.

https://doi.org/10.1182/blood.V110.11.3327.3327

Published: 2007

NARROW

The Cost of Managing Pleural Effusion Associated with Dasatinib in CML Patients Post Imatinib Failure.

Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.

Comparison of 12-Month Treatment Costs for Patients with Advanced Phase Chronic Myeloid Leukemia (CML) in China: Imatinib (IM) vs. Chemotherapy (Chemo) Plus Interferon-(IFN) in Accelerated Phase (AP) CML and IM vs. Chemo in Blast Crisis (BC) CML.

Imatinib Is Cost-Effective Comparing to Interferon-(IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective.

Imatinib Versus Interferon-alpha (IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective: 12 Months Cost and Cost Per Responder Analyses.

The Treatment Cost To Achieve a Complete Cytogenetic Response in Imatinib Resistant Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients: Nilotinib vs. Dasatinib.

Email alerts

ASH Publications

American Society of Hematology

The Cost of Managing Pleural Effusion Associated with Dasatinib in CML Patients Post Imatinib Failure.

Short-Term Cost Per Responder among New Tyrosine Kinase Inhibitors for Imatinib-Resistant CML in Chronic Phase (CML-CP) — Canada and Germany Perspectives.

Comparison of 12-Month Treatment Costs for Patients with Advanced Phase Chronic Myeloid Leukemia (CML) in China: Imatinib (IM) vs. Chemotherapy (Chemo) Plus Interferon-(IFN) in Accelerated Phase (AP) CML and IM vs. Chemo in Blast Crisis (BC) CML.

Imatinib Is Cost-Effective Comparing to Interferon-(IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective.

Imatinib Versus Interferon-alpha (IFN) for Patients with Newly Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML) from the Chinese Public Healthcare System Perspective: 12 Months Cost and Cost Per Responder Analyses.

The Treatment Cost To Achieve a Complete Cytogenetic Response in Imatinib Resistant Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients: Nilotinib vs. Dasatinib.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only